XNAS · PTN
+0.49% · +$0.0500 · Vol 41.7K
After hours · updated 16:00:00 ET
Palatin Technologies, Inc. Common Stock

Palatin Technologies, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$10.27
Card
Relationship Map

Follow $PTN

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $PTN by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology

snapshot unavailable for PTN. Cause unavailable.

Sentiment absence reason unknown
PTN
Palatin Technologies, Inc. Common Stock
Stale score · Mon Sep 21 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

74/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Stale score · Mon Sep 21 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Wed 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PTN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PTN catalysts
About Palatin Technologies, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
1993
Employees
29
Country
US

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$10.66
Day high
$10.71
Day low
$10.00
Previous close
$10.22
52W high
$28.00
-63.32% from high
52W low
$7.36
14% of range
Market cap
$18.2M
EPS
$-4.5467
Beta
-0.18
Shares out
1.8M
Volume
41.7K
0.36× rel vol
Avg volume
115.3K
VWAP
$10.45
Price history computed in-house
1W
-6.12%
1M
+5.99%
3M
-3.11%
YTD
-33.22%
SMA 50 $9.72 · above
SMA 200 $15.70 · below
52W position 14%

PTN overview

Veridion Score
74
Registered · 2026-09-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PTN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PTN Form 4 filings
Public disclosures

Congress activity in PTN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PTN in the cached public ledger.

Federal contracts

PTN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PTN in this window.
Lobbying spend

PTN lobbying filings, year to date.

Registered lobbying filings matched to Palatin Technologies, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PTN in this window.
Loading news for PTN
Analyst ratings
Sovereign unlock shows live analyst consensus for PTN.
Options
Sovereign unlock shows live options positioning for PTN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.